Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.
Leuk Lymphoma
; 59(7): 1659-1665, 2018 07.
Article
in En
| MEDLINE
| ID: mdl-29179634
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia, Myeloid, Chronic-Phase
/
Antineoplastic Combined Chemotherapy Protocols
Type of study:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
/
Male
Language:
En
Journal:
Leuk Lymphoma
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
Year:
2018
Type:
Article
Affiliation country:
France